Romidepsin
- Generic Name
- Romidepsin
- Brand Names
- Istodax
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36N4O6S2
- CAS Number
- 128517-07-7
- Unique Ingredient Identifier
- CX3T89XQBK
- Background
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
- Indication
用于在已接受至少1次既往全身治疗的患者中皮肤T-细胞淋巴瘤的治疗(CTCL)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
- Associated Therapies
- -
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2003-08-07
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00066638
- Locations
- 🇺🇸
Montefiore Medical Center - Moses Campus, Bronx, New York, United States
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Promyelocytic Leukemia (M3)Adult Acute Myeloid Leukemia With Del(5q)
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT00062075
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
- Conditions
- Blastic Phase Chronic Myelogenous LeukemiaChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood Chronic Myelogenous LeukemiaChildhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial Ependymoma
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00053963
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
FR901228 in Treating Patients With Hematologic Cancer
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00042822
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2000-12-18
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 131
- Registration Number
- NCT00007345
- Locations
- 🇺🇸
City of Hope National Cancer Center, Duarte, California, United States
🇦🇺Royal Adelaide Hospital, Adelaide, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.